Добірка наукової літератури з теми "Kidney replacement therapy (KRT)"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Kidney replacement therapy (KRT)".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Kidney replacement therapy (KRT)"
Antlanger, Marlies, Marlies Noordzij, Moniek van de Luijtgaarden, Juan Jesus Carrero, Runolfur Palsson, Patrik Finne, Marc H. Hemmelder, et al. "Sex Differences in Kidney Replacement Therapy Initiation and Maintenance." Clinical Journal of the American Society of Nephrology 14, no. 11 (October 24, 2019): 1616–25. http://dx.doi.org/10.2215/cjn.04400419.
Повний текст джерелаThurlow, John S., Megha Joshi, Guofen Yan, Keith C. Norris, Lawrence Y. Agodoa, Christina M. Yuan, and Robert Nee. "Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy." American Journal of Nephrology 52, no. 2 (2021): 98–107. http://dx.doi.org/10.1159/000514550.
Повний текст джерелаHelve, Jaakko, Mikko Haapio, Per-Henrik Groop, and Patrik Finne. "Primary kidney disease modifies the effect of comorbidities on kidney replacement therapy patients’ survival." PLOS ONE 16, no. 8 (August 20, 2021): e0256522. http://dx.doi.org/10.1371/journal.pone.0256522.
Повний текст джерелаBonventre, Joseph V., Frank P. Hurst, Melissa West, Iwen Wu, Prabir Roy-Chaudhury, and Murray Sheldon. "A Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies." Clinical Journal of the American Society of Nephrology 14, no. 10 (September 27, 2019): 1539–47. http://dx.doi.org/10.2215/cjn.02570319.
Повний текст джерелаFu, Edouard L., Roemer J. Janse, Ype de Jong, Vera H. W. van der Endt, Jet Milders, Esmee M. van der Willik, Esther N. M. de Rooij, Olaf M. Dekkers, Joris I. Rotmans, and Merel van Diepen. "Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis." Clinical Kidney Journal 13, no. 4 (August 1, 2020): 550–63. http://dx.doi.org/10.1093/ckj/sfaa160.
Повний текст джерелаSkalec, Tomasz, Barbara Adamik, Katarzyna Kobylinska, and Waldemar Gozdzik. "Soluble Urokinase-Type Plasminogen Activator Receptor Levels as a Predictor of Kidney Replacement Therapy in Septic Patients with Acute Kidney Injury: An Observational Study." Journal of Clinical Medicine 11, no. 6 (March 19, 2022): 1717. http://dx.doi.org/10.3390/jcm11061717.
Повний текст джерелаKelly, Yvelynne P., Kavita Mistry, Salman Ahmed, Shimon Shaykevich, Sonali Desai, Stuart R. Lipsitz, David E. Leaf, et al. "Controlled Study of Decision-Making Algorithms for Kidney Replacement Therapy Initiation in Acute Kidney Injury." Clinical Journal of the American Society of Nephrology 17, no. 2 (December 15, 2021): 194–204. http://dx.doi.org/10.2215/cjn.02060221.
Повний текст джерелаCarriazo, Sol, and Alberto Ortiz. "The last pre-pandemic European Renal Association Registry report: age at start of kidney replacement therapy in Europe." Clinical Kidney Journal 15, no. 3 (December 15, 2021): 393–96. http://dx.doi.org/10.1093/ckj/sfab274.
Повний текст джерелаZhao, Rui, Qing Zhou, Xiao-Wen Wang, Cui-Hua Liu, Mo Wang, Qing Yang, Yi-Hui Zhai, et al. "COVID-19 Outbreak and Management Approach for Families with Children on Long-Term Kidney Replacement Therapy." Clinical Journal of the American Society of Nephrology 15, no. 9 (July 14, 2020): 1259–66. http://dx.doi.org/10.2215/cjn.03630320.
Повний текст джерелаClark, Edward G., Swapnil Hiremath, Steven D. Soroka, Ron Wald, Matthew A. Weir, John Antonsen, Cheryl Banks, et al. "CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury." Canadian Journal of Kidney Health and Disease 7 (January 2020): 205435812094167. http://dx.doi.org/10.1177/2054358120941679.
Повний текст джерелаДисертації з теми "Kidney replacement therapy (KRT)"
Khan, Izhar H. "Outcomes and management in renal replacement therapy." Thesis, University of Aberdeen, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.295796.
Повний текст джерелаOh, Weng Chin. "Micronutrient losses during renal replacement therapy for acute kidney injury." Thesis, University of Nottingham, 2017. http://eprints.nottingham.ac.uk/41567/.
Повний текст джерелаArgaw, Peniel N. (Peniel Neway). "Effect of renal replacement therapy on acute kidney injury in sepsis patients." Thesis, Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/119740.
Повний текст джерелаThis electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.
Cataloged from student-submitted PDF version of thesis.
Includes bibliographical references (pages 39-40).
According to the Centers for Disease Control and Prevention, there are approximately 1.5 million cases of sepsis and over 250,000 resultant deaths each year [1]. One of the major effects of sepsis is organ failure, notably in the kidneys, lungs, liver, and brain. In the case where the kidneys fail, renal replacement therapy (RRT) may be performed in order to sustain the functionality of the kidneys and overall ameliorate patients' outcomes. The goal of this work is to determine the relationship between undergoing RRT and patient outcome. The Philips-MIT eICU Collaborative Research Database was used to identify patients with sepsis and acute kidney injury, and split the cohort into those who had undergone RRT and those who did not. Multivariate logistic regression and propensity score analysis were utilized to evaluate the treatment effect on mortality. The patients who underwent RRT had a significantly better outcome than those who did not (odds ratio = 0.260465, 95% confidence interval = 0.211568 to 0.320664, p<0.001). From the filtered patients, the percentage of men to women increased with those who underwent RRT (55.08% vs. 53.78%) as well as the percentage of African Americans (25% vs. 15.63%) and Other (5.86% vs. 4.04%) ethnicities. In addition to gender and ethnicity, other covariates such as Sequential Organ Failure Assessment score, cirrhosis, and metastatic cancer had a great impact on patient outcomes. This work concludes that RRT does in fact benefit the patient outcome and dialysis is a statistically significant feature within the dataset.
by Peniel N. Argaw.
M. Eng.
Mapiye, Darlington Shingirirai. "Computational genomics approaches for kidney diseases in Africa." University of the Western Cape, 2015. http://hdl.handle.net/11394/4958.
Повний текст джерелаEnd stage renal disease (ESRD), a more severe form of kidney disease, is considered to be a complex trait that may involve multiple processes which work together on a background of a significant genetic susceptibility. Black Africans have been shown to bear an unequal burden of this disease compared to white Europeans, Americans and Caucasians. Despite this, most of the genetic and epidemiological advances made in understanding the aetiology of kidney diseases have been done in other populations outside of sub-Saharan Africa (SSA). Very little research has been undertaken to investigate key genetic factors that drive ESRD in Africans compared to patients from rest of world populations. Therefore, the primary aim of this Bioinformatics thesis was twofold: firstly, to develop and apply a whole exome sequencing (WES) analysis pipeline and use it to understand a genetic mechanism underlying ESRD in a South African population of mixed ancestry. As I hypothesized that the pipeline would enable the discovery of highly penetrate rare variants with large effect size, which are expected to explain an important fraction of the genetic aetiology and pathogenesis of ESRD in these African patients. Secondly, the aim was to develop and set up a multicenter clinical database that would capture a plethora of clinical data for patients with Lupus, one of the risk factors of ESRD. From WES of six family members (five cases and one control); a total of 23 196 SNVs, 1445 insertions and 1340 deletions, overlapped amongst all affected family members. The variants were consistent with an autosomal dominant inheritance pattern inferred in this family. Of these, only 1550 SNVs, 67 insertions and 112 deletions were present in all affected family members but absent in the unaffected family member. Following detailed evaluation of evidence for variant implication and pathogenicity, only 3 very rare heterozygous missense variants in 3 genes COL4A1 [p.R476W], ICAM1 [p.P352L], COL16A1 [p.T116M] were considered potentially disease causing. Computational relatedness analysis revealed approximate amount of DNA shared by family members and confirmed reported relatedness. Genotyping for the Y chromosome was additionally performed to assist in sample identity. The clinical database has been designed and is being piloted at Groote Schuur medical Hospital at the University of Cape Town. Currently, about 290 patients have already been entered in the registry. The resources and methodologies developed in this thesis have the potential to contribute not only to the understanding of ESRD and its risk factors, but to the successful application of WES in clinical practice. Importantly, it contributes significant information on the genetics of ESRD based on an African family and will also improve scientific infrastructure on the African continent. Clinical databasing will go a long way to enable clinicians to collect and store standardised clinical data for their patients.
Nicholas, Pauline. "Impaired cognition in end stage kidney disease: Prevalence, predictors and differences between treatment." Thesis, Queensland University of Technology, 2020. https://eprints.qut.edu.au/203098/1/Pauline_Nicholas_Thesis.pdf.
Повний текст джерелаAlasmari, Hajar Ali M. "Examining intensive care nurses' clinical decision-making associated with acute kidney injury and continuous renal replacement therapy in Saudi Arabia." Thesis, Queensland University of Technology, 2018. https://eprints.qut.edu.au/122877/1/Hajar%20Ali%20M_Alasmari_Thesis.pdf.
Повний текст джерелаLima, Andréia Barbosa de [UNESP]. "Estresse, depressão e suporte familiar em pacientes em diálise peritoneal e hemodiálise." Universidade Estadual Paulista (UNESP), 2016. http://hdl.handle.net/11449/138927.
Повний текст джерелаRejected by Ana Paula Grisoto (grisotoana@reitoria.unesp.br), reason: Solicitamos que realize uma nova submissão seguindo a orientação abaixo: O arquivo submetido está sem a ficha catalográfica e não contém o certificado de aprovação. A versão submetida por você é considerada a versão final da dissertação/tese, portanto não poderá ocorrer qualquer alteração em seu conteúdo após a aprovação. Corrija esta informação e realize uma nova submissão contendo o arquivo correto. Agradecemos a compreensão. on 2016-05-31T19:09:31Z (GMT)
Submitted by ANDREIA BARBOSA DE LIMA null (deiablima@hotmail.com) on 2016-06-01T10:06:58Z No. of bitstreams: 2 Defesa Andréia.pdf: 1245934 bytes, checksum: a1a3f246da64178e5fb9306ef619a0d4 (MD5) Defesa Andréia.pdf: 1654449 bytes, checksum: d9d4103fa5b658e22b8e4ae88ea17897 (MD5)
Rejected by Ana Paula Grisoto (grisotoana@reitoria.unesp.br), reason: Solicitamos que realize uma nova submissão seguindo as orientações abaixo: Foram submetidos 2 arquivos PDF’s, apenas 1 arquivo deve ser submetido Corrija estas informações e realize uma nova submissão contendo o arquivo correto. Agradecemos a compreensão. on 2016-06-01T12:45:54Z (GMT)
Submitted by ANDREIA BARBOSA DE LIMA null (deiablima@hotmail.com) on 2016-06-01T13:06:47Z No. of bitstreams: 1 Defesa Andréia.pdf: 1654449 bytes, checksum: d9d4103fa5b658e22b8e4ae88ea17897 (MD5)
Approved for entry into archive by Ana Paula Grisoto (grisotoana@reitoria.unesp.br) on 2016-06-01T13:34:38Z (GMT) No. of bitstreams: 1 lima_ab_me_bauru.pdf: 1654449 bytes, checksum: d9d4103fa5b658e22b8e4ae88ea17897 (MD5)
Made available in DSpace on 2016-06-01T13:34:38Z (GMT). No. of bitstreams: 1 lima_ab_me_bauru.pdf: 1654449 bytes, checksum: d9d4103fa5b658e22b8e4ae88ea17897 (MD5) Previous issue date: 2016-03-10
As doenças crônicas na atualidade têm recebido atenção especial das organizações que tratam da saúde. Essas doenças repercutem de diversas maneiras no cotidiano do indivíduo, envolvendo seus aspectos físico, psicológico e social. Uma das doenças crônicas que está incidindo de forma negativa na vida do sujeito é a Doença Renal Crônica (DRC), a qual se refere à alteração na função do rim, de modo que, quando avançada leva o paciente a iniciar a Terapia Renal Substitutiva (TRS). Os dois métodos de TRS são a hemodiálise (HD) e a diálise peritoneal (DP), o primeiro é realizado em ambiente ambulatorial e o segundo em domicílio. Nesse sentido, o objetivo deste estudo foi relacionar a presença de estresse e depressão considerando a percepção de suporte familiar em pacientes em diálise peritoneal e hemodiálise, associada a dados demográficos. Participaram da pesquisa 77 sujeitos que realizam TRS, esses foram divididos em dois grupos, 47 pacientes que realizam HD ambulatorial e 30 pacientes em DP domiciliar de dois centros de diálise. Os instrumentos foram Questionário Sociodemográfico, Inventário de Sintomas de Stress para Adultos de Lipp (ISSL), Inventário de Percepção de Suporte Familiar (IPSF) e Escala Baptista de Depressão (EBADEP-Hosp-Amb). A análise dos dados foi realizada pelos testes Mann Whitney e Kruskal Wallis. Os resultados desse estudo apontaram que os pacientes em DP apresentam maior sintomatologia de estresse do que os que realizam HD, no que se refere à sintomatologia de depressão, os dois grupos apresentaram baixa sintomatologia, e em relação a percepção do suporte familiar, os pacientes em DP mantiveram a classificação Alta e os em HD Médio-Alto. No que tange aos cruzamentos dos dados com os sociodemográficos, houve ocorrência de significância estatística para o grupo de HD em relação ao gênero, estado civil, satisfação com a religião, suporte religioso e tempo de tratamento. Os achados referentes ao grupo de DP contrariaram a hipótese, apresentando maior frequência de estresse comparado aos pacientes que realizam HD. Este trabalho apresentou algumas limitações como o número de pacientes e possibilidade de comparação com outros estudos com a mesma amostra e instrumentos utilizados. No entanto, sua relevância na área da Psicologia e interface com outras áreas da saúde pode ser a semente para outros projetos a fim de minimizarem a dor pela qual tantos pacientes estão expostos diante da doença e tratamento.
Chronic diseases nowadays are receiving special attention from the health organizations. These diseases reverberate in different ways in the daily life of the individual, involving its physical, psychological and social aspects. One of the chronic diseases that is incurring in a negative way on the person’s life is the Chronic Kidney Disease (DRC), which refers to the kidney’s function alteration, in such way that, when advanced, it takes the patient to start Kidney Replacement Therapy (TRS). The two TRS methods are hemodialysis (HD) and peritoneal dialysis (DP); the first is done in an ambulatory ambient and the second at home. In these terms, the purpose of this study was to relate the presence of stress and depression considering the perception of family support in patients in peritoneal dialysis and hemodialysis, associated to demographic data. 77 people who passed through TRS were part of this research, those were divided in two groups, 47 patients who did ambulatory HD and 30 patients who did DP at home from two dialysis center. The instruments were the Sociodemographic Questionnaire, Lipp's Inventory of Symptoms of Stress for Adults (ISSL), Perception of Family Support Inventory (IPSF) and Baptista's Depression Scale (EBADEP-Hosp-Amb). This study’s results pointed the patients in DP presented bigger symptomatology of stress than the ones in HD. In the matter of depression’s symptomatology, both groups presented low symptomatology, and in relation to the family’s support perception, the patients in DP maintained a High classification and the ones in HD, Medium-High. Concerning the crossing of the data with the Sociodemographics, there was an occurrence of statistical significance for the group in HD in regarding the genre, marital status, fulfillment with religion, religious support and time of treatment. What was found in relation to the group in DP contradicted the hypothesis, presenting more frequency of stress compared to the patients in HD. This study presented some limitations such as the number of patients and possibility of comparison to other studies with the same sample and instruments used. However, its importance on the Psychology field and interface with other health areas can be a seed for other projects in order to minimize the pain to which so many patients are exposed before the disease and treatment.
Ulldemolins, Gómez Marta. "Optimization of meropenem and piperacillin dosing in critically ill patients with septic shock and acute kidney injury requiring continuous renal replacement therapy: a pharmacokinetic and pharmacodynamic study." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/585924.
Повний текст джерелаL’administració precoç d’antibioteràpia apropiada ha demostrat ser la intervenció més eficaç per reduir la mortalitat en pacients crítics amb xoc sèptic i síndrome de disfunció multiorgànica (SDMO). Malgrat la seva rellevància, però, la dosificació antibiòtica en els pacients amb SDMO incloent insuficiència renal aguda (IRA) que requereixen teràpia continua de suport renal (TCSR) encara representa un repte diari pels professionals de la salut. Al nostre medi, els antibiòtics beta[lactàmics d’ampli espectre meropenem i piperacilelina (en combinació amb tazobactam) són els antibiòtics més prescrits a aquests pacients d’altíssima complexitat i gravetat. L'impacte del xoc sèptic, la IRA i la TCSR en els requeriments de dosis d'aquests fàrmacs és vital, ja que tant la pròpia malaltia com les intervencions mèdiques produeixen alteracions significatives en la seva farmacocinètica (FC), que duen a variacions en els perfils concentració[temps i, conseqüentment, comprometen l'assoliment de concentracions del fàrmac dins del rang terapèutic. No obstant això, individualitzar la dosificació de meropenem i piperacilelina en pacients amb xoc sèptic, IRA i requeriment de TCSR és encara molt complex. HIPÒTESI: La dosificació de meropenem i piperacilelina en pacients crítics amb xoc sèptic i IRA que requereixen TCSR és sub[òptima degut a les variacions en el comportament FC dels fàrmacs produïdes tant per la malaltia com pel maneig mèdic d’aquesta. Aquestes variacions FC poden comprometre l'assoliment de concentracions terapèutiques. OBJECTIUS: 1. Avaluar la idoneïtat de les recomanacions actuals sobre dosificació de meropenem i piperacilelina en pacients crítics amb xoc sèptic i IRA que requereixen TCSR; 2. Identificar les fonts de variabilitat que comprometen l’exposició òptima a aquests antibiòtics en la nostra població de pacients; i 3. Desenvolupar noves recomanacions per individualitzar la dosificació d’aquests antibiòtics tenint en compte aquestes fonts de variabilitat. METODOLOGIA: En base a la hipòtesi i els objectius, s’han desenvolupat els tres estudis següents: Estudi 1: Revisió de la literatura. S’ha realitzat una revisió sistemàtica i avaluació crítica de l'evidència disponible sobre la dosificació de meropenem i piperacilelina en pacients crítics amb xoc sèptic, IRA i requeriment de TCSR. Estudis 2 i 3: Caracterització de la FC de meropenem i piperacilelina en pacients crítics amb xoc sèptic i IRA que requereixen TCSR. S’han realitzat dos estudis farmacocinètics multicèntrics, oberts, prospectius observacionals, a les Unitats de Medicina Intensiva de tres hospitals espanyols de tercer nivell. S’han inclòs a l’estudi 30 pacients amb xoc sèptic, IRA i TCSR que rebien meropenem i 19 pacients que rebien piperacilelina. Amb les dades procedents d’aquests pacients, s’han desenvolupat i validat dos models FC poblacionals, a partir dels quals s’han realitzat simulacions de Monte Carlo de diferents esquemes terapèutics (mitjançant el software NONMEM v.7.3®). RESULTATS: La principal troballa de l'estudi 1 és que les recomanacions actuals de dosificació de meropenem i piperacilelina en pacients crítics amb xoc sèptic i IRA que requereixen TCSR es basen en estudis amb algunes limitacions, com ara: 1) diferents nivells de gravetat de la malaltia i de disfunció renal, 2) diferents diagnòstics d’ingrés (mèdic versus quirúrgic versus trauma), 3) diferents maneigs clínics, principalment referent a les característiques de la TCSR, 4) metodologies heterogènies d’anàlisi FC, i 5) diferents objectius farmacodinàmics (FD) en base als quals es fan les recomanacions de dosificació. Això compromet l'extrapolació dels resultats d’aquests estudis a la nostra població de pacients. Posteriorment, els estudis 2 i 3 han identificat importants fonts de variabilitat en la FC de meropenem i piperacilelina, que si es consideren en el moment de la dosificació poden ser útils per individualitzar el tractament antibiòtic. Pel que fa a meropenem, la principal conclusió de l'anàlisi FC poblacional és la relació existent entre la diüresi acumulada de 24h i l’aclariment total de meropenem (CL). Els pacients amb diüresi conservada (>500ml/24h) presenten un increment d’almenys el 30% sobre el CL total de meropenem en comparació amb aquells pacients anúrics (<100mL/24h), sent aquest augment en el CL del fàrmac directament proporcional al volum d'orina. Posteriorment, les simulacions de Monte Carlo basades en aquest model FC poblacional han demostrat que per tal de mantenir les concentracions de meropenem per damunt de la concentració mínima inhibitòria (CMI) dels bacteris durant un 100% de l'interval de dosificació (100% FuT>CMI), els pacients oligo[anúrics (diüresi residual de 0[500mL/24h) requereixen 500mg/q8h administrats en un bolus de 30 minuts per al tractament de microorganismes susceptibles (CMI <2 mg/L), mentre que els pacients amb diüresi conservada (>500mL/24h) requereixen la mateixa dosi administrada mitjançant una perfusió de 3h. Pel tractament de microorganismes amb una CMI propera al límit de susceptibilitat (2[ 4mg/L) és necessària una dosi de 500mg/q6h: administrada en un bolus de 30 minuts de en pacients oligo[anúrics i mitjançant una perfusió de 3h en pacients amb una diüresi conservada. Si s’escull un objectiu FD més conservador, (40% FuT>CMI), una dosi de 500mg/q8h administrada en un bolus de 30 minuts és suficient amb independència de la diüresi residual. Pel que fa a la piperacilelina, la principal conclusió de l'anàlisi FC poblacional és la relació existent entre el tipus de membrana utilitzada per la TCSR, el pes del pacient i el CL total de piperacilelina; per a un pes de 80 kg, el CL total de piperacilelina es duplica quan es fa servir una membrana d’1,5m2 de copolímer d’acrilonitril i sulfat sòdic de metalelil amb un recobriment d’heparina i polietilenimina (AN69ST) en comparació amb el CL total observat quan es fa servir un filtre AN69 convencional de 0,9m2. Posteriors simulacions de Monte Carlo han demostrat que per a un objectiu FD de 100% FuT>CMI, els pacients que reben TCSR amb membranes AN69ST d’1,5m2 requereixen dosis de 4000mg/q8h per al tractament de microorganismes amb CMI properes al límit de susceptibilitat (CMI = 8[ 16mg/L). Per contra, 2000mg/q8h són suficients per als pacients que reben TCSR amb membranes AN69 de 0,9 m2. Per al tractament de soques d’alta susceptibilitat a la piperacilelina (CMI ≤ 4mg/L), o per l’assoliment d'un objectiu FD més conservador (50% FuT>CMI), 2000mg/q8h són suficients en tots els casos.
Galiyeva, Dinara. "Cardiovascular risk factor prevalence, mortality and cardiovascular disease incidence in patients who initiated renal replacement therapy in childhood : systematic review and analyses of two renal registries." Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/28837.
Повний текст джерелаLeusin, Fabiane. "Farmacocinética do Meropenem infundido por 3 horas em pacientes criticamente enfermos em terapia renal substitutiva contínua." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2012. http://hdl.handle.net/10183/48990.
Повний текст джерелаContinuous renal replacement therapy (CRRT) is widely used in critically ill patients with acute kidney injury (AKI). Meropenem is a carbapenem used in critically ill patients, which has a time dependent antibacterial activity. The aim of the study was to assess the pharmacokinetics of meropenem on a 3-hour infusion in patients undergoing CRRT due to AKI. We studied the plasmatic and effluent concentrations in five patients undergoing CRRT. The samples were collected at moments 0, 30 minutes, and 1, 2, 4, 6 and 8 hours after the beginning of the 3-hour infusion. The meropenem determinations were made through high performace efficiency liquid chromatography (HPLC). Four male patients and one female patient, with a mean age of 53,0 ± 19,7 (23 to 80 years), weighing 62,1 ± 10,6 kgs were studied. Pharmacokinetic parameters presented in medians (range): plasmatic concentrations, 34.86mg / L (10,08-139,27); half-life (t ½), 1,8 h (1,4-3,0); volume of distribution (Vd), 8,29 L (5,8-15,3); total clearance (CLT) 3,98 L / h (2,51-4,35); (Cmax) (maximum plasma concentration), 48,5 mg / L (37,0-105,8); Cmin (minimum plasma concentration)20,1 mg / L (14,0-16,6); elimination constant (Kel), 0,38 (0,34-0,43); area under the concentration versus time curve (AUC 0 a 8 h), 251,1 mg / Lh (229,7-398,4); (AUC 0 a ∞) 275,1 mg / Lh (263,8-453,6). In the effluent, the maximum concentrations varied from 24,35 to 74,81 mg/L, and the clearance from the therapy varied from 8,46 to 18,33 ml/min. The elimination of meropenem through CRRT is similar to that of a normal kidney, given a 3-hour infusion every 8 hours. Plasmatic levels were always above the necessary MICs. We can conclude there was no need for dose adjustment of meropenem with the prescribed CRRT dose.
Книги з теми "Kidney replacement therapy (KRT)"
V, Bonomini, and Università di Bologna, eds. Biotechnology in renal replacement therapy. Basel: Karger, 1989.
Знайти повний текст джерелаP, Paganini Emil, ed. Acute continuous renal replacement therapy. Boston: M. Nijhoff, 1986.
Знайти повний текст джерелаControversies in acute kidney injury. Basel: Karger, 2011.
Знайти повний текст джерелаSara, Blakeley, ed. Renal failure and replacement therapies. London: Springer, 2008.
Знайти повний текст джерелаRonco, C., and Ding Xiaoqiang. Acute kidney injury. Basel: Karger, 2016.
Знайти повний текст джерелаClaude, Jacobs, ed. Optimal treatment strategies in end-stage renal failure. Oxford: Oxford University Press, 2002.
Знайти повний текст джерелаInternational, Course on Critical Care Nephrology (3rd 2004 Vicenza Italy). Sepsis, kidney and multiple organ dysfunction: Proceedings of the Third International Course on Critical Care Nephrology, Vicenza, June 1-4, 2004. Basel: Karger, 2004.
Знайти повний текст джерелаMarshall, Mark R. Intermittent acute renal replacement therapy. Edited by Norbert Lameire. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0233_update_001.
Повний текст джерелаGolper, Thomas A., Andrew A. Udy, and Jeffrey Lipman. Drug dosing in acute kidney injury. Edited by William G. Bennett. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0364.
Повний текст джерелаRonco, Claudio, Rinaldo Bellomo, and John A. Kellum. Continuous Renal Replacement Therapy. Oxford University Press, Incorporated, 2016.
Знайти повний текст джерелаЧастини книг з теми "Kidney replacement therapy (KRT)"
Rayner, Hugh, Mark Thomas, and David Milford. "Renal Replacement Therapy." In Understanding Kidney Diseases, 255–74. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-23458-8_18.
Повний текст джерелаBouchard, Josée, Roy Mathew, and Ravindra L. Mehta. "Stopping Acute Kidney Replacement Therapy." In Management of Acute Kidney Problems, 617–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-69441-0_60.
Повний текст джерелаTroutman, Hannah Roni. "Preparation for Renal Replacement Therapy." In Approaches to Chronic Kidney Disease, 411–23. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83082-3_23.
Повний текст джерелаNegi, Shigeo, Masaki Ohya, and Takashi Shigematsu. "Renal Replacement Therapy in AKI." In Acute Kidney Injury and Regenerative Medicine, 239–54. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-1108-0_17.
Повний текст джерелаNeirynck, Nathalie, and An S. De Vriese. "Indications to Start Kidney Replacement Therapy." In Management of Acute Kidney Problems, 471–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-69441-0_47.
Повний текст джерелаSymons, Jordan M. "Acute Kidney Replacement Therapy in Children." In Management of Acute Kidney Problems, 609–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-69441-0_59.
Повний текст джерелаJörres, Achim, and Dinah Jörres. "Choosing a Therapy Modality for Acute Renal Replacement Therapy." In Management of Acute Kidney Problems, 603–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-69441-0_58.
Повний текст джерелаGomes da Costa, A., M. J. Sampaio, A. Sousa, A. M. Correia, and J. R. Pena. "Immunological Criteria in Kidney Allocation." In Organ Replacement Therapy: Ethics, Justice Commerce, 419–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76444-8_64.
Повний текст джерелаWen, Ping. "Initiation Timing and Modality Option for Renal Replacement Therapy." In Chronic Kidney Disease, 199–207. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9131-7_16.
Повний текст джерелаAssadi, Farahnak, and Fatemeh Ghane Sharbaf. "Introduction: Acute Kidney Injury and Continuous Renal Replacement Therapy." In Pediatric Continuous Renal Replacement Therapy, 1–34. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-26202-4_1.
Повний текст джерелаТези доповідей конференцій з теми "Kidney replacement therapy (KRT)"
Johnson, Emma, Krishna Shah, Ananna Rahman, Kieran Mccafferty, Simon Tiberi, and Heinke Kunst. "Extrapulmonary tuberculosis in patients with chronic kidney disease receiving renal replacement therapy." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2976.
Повний текст джерелаSanthanakrishnan, Arvind, Trent Nestle, Brian Moore, Ajit P. Yoganathan, and Matthew L. Paden. "Characterization of a Low Extracorporeal Volume, High Accuracy Pediatric Continuous Renal Replacement Therapy Device." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80210.
Повний текст джерелаM’pembele, R., S. Roth, A. Stroda, G. Lurati Buse, R. Westenfeld, I. Tudorache, H. Aubin, et al. "Risk Factors for Acute Kidney Injury Requiring Renal Replacement Therapy after Orthotopic Heart Transplantation in Patients with Preserved Renal Function." In 51st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1742818.
Повний текст джерелаFukui, T., M. Aosaki, Y. Uetsuka, K. Iwade, T. Nirei, and K. Hirosawa. "THROMBOEMBOLISM IN PROSTHETIC VALVE ENDOCARDITIS AND ANTICOAGULANT THERAPY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643267.
Повний текст джерелаPerez Ingles, D., A. Illescas, N. Perryman Collins, N. Jordyn A, J. L. Marinaro, C. Argyropoulos, and J. P. Teixeira. "Impact of COVID-19 Pandemic on Crude Mortality Rates Associated with Acute Kidney Injury Requiring Continuous Renal Replacement Therapy: A Single-Center Study." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2582.
Повний текст джерелаSedhai, Y. R., R. Baniya, A. Koirala, S. Basnyat, and B. Shrestha. "Early Vs Late Initiation of Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury, Updated Systematic Review, and Meta-Analysis of Randomized Controlled Trials." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6312.
Повний текст джерелаЗвіти організацій з теми "Kidney replacement therapy (KRT)"
Xiao, Chuan, Feng Shen, Yumei Cheng, and Jingjing Xiao. Timing of initiation of renal replacement therapy for acute kidney injury: a meta-analysis with trial sequential analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2020. http://dx.doi.org/10.37766/inplasy2020.12.0030.
Повний текст джерела